The MYG1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HT29 human colorectal adenocarcinoma cell line. This product creates a loss-of-function model for the MYG1 gene, which encodes a mitochondrial protein essential for ribosome biogenesis and cell proliferation. The polyclonal format ensures a heterogeneous mixture of edited cells, enabling robust functional studies without the biases of single-cell cloning. It serves as a versatile tool for investigating gene function in mitochondrial biology and cancer research.
The HT29 cell line originates from a human colorectal adenocarcinoma and exhibits an epithelial morphology. It is extensively used as a model system in cancer biology and intestinal epithelial research due to its well-characterized genetic alterations, including mutations in APC, TP53, and ??-catenin pathways. HT29 cells retain key features of colorectal cancer, such as aberrant proliferation and tumorigenic potential, making them a clinically relevant host for studying oncogenic mechanisms, drug responses, and mitochondrial function in the context of colorectal cancer.
MYG1 is a mitochondrial protein critically involved in ribosome biogenesis and RNA processing, underpinning mitochondrial translation and cellular proliferation. It acts downstream of cyclins and CDKs, which coordinate its activity with cell cycle progression. Within mitochondria, MYG1 interacts with MRPLs and MRPSs, contributing to ribosome assembly alongside mitochondrial RNA polymerase and GTPases. Disruption of MYG1 thus impairs ribosome formation, leading to defective mitochondrial function and reduced cell growth, highlighting its role in linking proliferation to mitochondrial biogenesis.
In HT29 colorectal adenocarcinoma cells, MYG1 knockout creates a powerful model to investigate the contribution of mitochondrial ribosome biogenesis to cancer cell proliferation. Colorectal cancer cells often exploit mitochondrial metabolic pathways to support rapid growth, and loss of MYG1 disrupts mitochondrial protein synthesis, thereby sensitizing cells to metabolic stress. This system is valuable for dissecting the mitochondrial dependencies of colorectal tumors, exploring therapeutic windows, and understanding how cell cycle signals interface with organellar function. The model also provides a platform for evaluating the role of MYG1 in disease progression and drug resistance.
These polyclonal MYG1 knockout HT29 cells are suited for a broad range of experimental applications. Functional studies of mitochondrial ribosome biogenesis may employ cell proliferation assays (MTT, BrdU), western blotting for mitochondrial ribosomal proteins, and RT-qPCR for mitochondrial-encoded transcripts. Mitochondrial respiration can be assessed by Seahorse analysis, while clonogenic assays evaluate long-term growth capacity. Transcriptomic approaches such as RNA-seq reveal global gene expression changes upon MYG1 loss. Collectively, these methods support colorectal cancer modeling, anti-cancer drug screening, and investigations into mitochondrial gene expression regulation. For additional details or assay development support, contact Ascent Research.
